Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The Download: unraveling a death threat mystery, and AI voice recreation for musicians

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: unraveling a death threat mystery, and AI voice recreation for musicians Date: 2026-02-16 13:10 Source: https://www.technologyreview.com/2026/02/16/1133008/the-download-unraveling-a-death-threat-mystery-and-ai-voice-recreation-for-musicians/ <p><em>This is today’…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Google downplays safety warnings on AI-generated medical advice by only displaying extended warnings when a user clicks 'Show more'

    80% confidence
  • Nukes are a hot topic across Europe right now

    80% confidence
  • China figured out how to sell EVs but now must deal with aging batteries

    80% confidence
  • Influencers and TikTokers feeding babies butter is not supported by scientific evidence

    80% confidence
  • The creator of OpenClaw joining OpenAI demonstrates how seriously OpenAI is taking agents

    80% confidence
  • AI promises to make better, more immersive video games, but those are lofty goals that may never be achieved

    80% confidence
  • US automakers fear Trump may greenlight Chinese carmakers to build plants in the US

    80% confidence
  • AI bots writing scathing posts about individuals is currently just a baby version but incredibly concerning for the future

    80% confidence
  • AI companies have stopped warning users that their chatbots are not doctors

    80% confidence
  • 55% of Americans believe the Fruit of the Loom logo includes a cornucopia, 25% are unsure, and only 21% are confident it does not, according to a 2022 poll

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com